The U.S. Food and Drug Administration (FDA) has issued a new round of warnings and advisory letters to makers of dietary supplements, telling them not to falsely claim their products cure, prevent or treat serious diseases. Last year the FDA and the Federal Trade Commission sent warning letters to makers and distributors of 12 products sold as treatments for opioid addiction and withdrawal.
A new study finds many pharmacies in California don’t offer the opioid overdose antidote naloxone without a prescription, even though state law has allowed pharmacists to furnish naloxone without a physician’s prescription since 2016.
Making the opioid addiction medication buprenorphine more widely available outweighs the risk the drug will be diverted, addiction experts tell NPR. President Trump is expected to sign a bill that would increase access to the medication.
U.S. Surgeon General Jerome M. Adams released a report Thursday that recommends ways families, doctors, educators and business leaders can talk about and prevent addiction, according to The Washington Times.
Google will once again accept advertising from U.S. addiction treatment centers, Reuters reports. A company based in Portland, Oregon will vet the ads. Last year, Google suspended treatment center ads after it was found many of them were deceptive and misleading.